Observational studies of other GLP-1 receptor agonists used for over a decade have not demonstrated a consistent signal for increased MTC incidence in human populations, though data on overall thyroid cancer have shown mixed results
Overall, while there is a potential for muscle mass changes, the effects of GLP-1 agonists on muscle are influenced by several factors, including the patients overall health, diet, and exercise habits
For the future, scientists are investigating how it could address metabolic disorders other than obesity, including non-alcoholic fatty liver disease and insulin resistance
These could include claims for compensation for medical expenses, lost wages, and pain and suffering
Industry case studies (beyond Roche) include: Siemens and digital pharma: Siemens has published about using twins from lab R&D to manufacturing, pointing out that Pharma 4.0 (the intelligent factory) uses twins to realize end-to-end digitalization ( [30] )
What does a normal injection site reaction look like with semaglutide